Close Menu

NEW YORK (GenomeWeb) – Cofactor Genomics announced today that it has partnered with the National Cancer Institute (NCI), in addition to agreements with three other unnamed academic and pharma groups, to demonstrate the clinical utility of Cofactor's RNA-based immune-profiling assay, Cofactor Paragon.

Under the terms of their material transfer agreement, the collaborators will use clinical specimens from several of NCI's clinical trials to validate the Paragon assay.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A bill passed by a US House of Representatives appropriations subcommittee would give scientific agencies including the National Science Foundation boosts in funding.

University of Idaho researchers model the scientific discovery process to examine the link between reproducibility and scientific truth.

Relocating USDA agencies outside of Washington, DC, may make them less effective, critics of the move tell NPR.

In PLOS this week: genes that help Borrelia burgdorferi survive in ticks, CiliaCarta collection of about 1,000 suspected cilia genes, and more.